Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ankaferd Sağlık Ürünleri is a Turkish biotechnology company specializing in the development and manufacture of Ankaferd Blood Stopper (ABS), a unique hemostatic agent. The product is derived from a standardized mixture of five medicinal plants: Urtica dioica, Vitis vinifera, Glycyrrhiza glabra, Alpinia officinarum, and Thymus vulgaris. ABS is distinguished by its mechanism of action, which involves the rapid formation of a protein network in plasma that aggregates erythrocytes independently of traditional coagulation factors. This allows the product to be effective even in patients with primary or secondary hemostasis disorders, such as hemophilia or those on anticoagulant therapy. The company's product line is utilized across various medical fields, including gastrointestinal endoscopy, dental surgery, and emergency medicine, to control both internal and external bleeding. Ankaferd holds international patents and CE certification for its products, which are available in formats such as sprays, tampons, and ampoules.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ankaferd Sağlık Ürünleri.